Immunocore (IMCR)
(Delayed Data from NSDQ)
$38.91 USD
-0.71 (-1.79%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $39.00 +0.09 (0.23%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
IMCR 38.91 -0.71(-1.79%)
Will IMCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for IMCR
Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up
Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat
5 Biotech Stocks to Consider for Your Portfolio in 2024
Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus
Other News for IMCR
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
Warning: IMCR is at high risk of performing badly
The Galien Foundation Announces 2024 International Prix Galien and Prix Galien Italy Award Winners
Yellowstone Biosciences launches with #16.5 million to pioneer soluble bispecific TCR-based therapies for cancer
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma